Proactive Investors - Run By Investors For Investors

Netscientific surges as peer-reviewed article confirms potential of PDS Biotech’s Versamune immunotherapy platform

In the article, researchers described how the Versamune platform recruits and activates killer T-cells to recognise and effectively attack cancer cells while simultaneously making cancer cells more susceptible to T-cell attack
cancer cell
The article was published online earlier this month and will be in next month’s print edition of Journal of Immunology

A peer-reviewed publication has given backing to a cancer immunotherapy platform developed by PDS Biotechnology Corporation (NASDAQ:PDSB) – one of Netscientific PLC’s (LON:NSCI) portfolio companies.

The article, published online earlier this month in the Journal of Immunology, describes how the Versamune platform recruits and activates T-cells.

READ: Netscientific soars as it sells stakes in Vortex and Wanda

T-cells are responsible for identifying and attacking cancer cells while at the same time making them more susceptible to T-cell attack.

A phase II study of PDS0101 – the lead drug from the Versamune platform – in combination with Merck’s Keytruda in head and neck cancer patients is due to kick off later this year.

Similar studies testing PDS0101 in advanced HPV-associated cancers and on its own in cervical dysplasia are also planned.

Shares in Netscientific, which owns 8.15% of PDS’s stock, rose 16.5% to 9.03p in late-afternoon trading on Thursday.

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
dna strand
May 08 2019
The latest update reveals the company significant clinical and commercial milestones in sight
Alliance
April 05 2019
Chief executive Peter Butterfield said the company has started 2019 well-positioned for growth after a strong performance in 2018.

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use